NCT04954469View on ClinicalTrials.gov

B-pVAC-SARS-CoV-2: Study to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

August 18, 2022

Study Completion Date

April 30, 2023

Conditions
Immune Deficiency Disease
Interventions
BIOLOGICAL

CoVAC-1

Peptide vaccination should be started as soon as possible after the screening visit.

Trial Locations (3)

12203

Charité - Universitätsmedizin Berlin Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie Charité Campus Benjamin Franklin, Berlin

60488

Krankenhaus Nordwest gGmbH Institut für Klinisch-Onkologische Forschung (IKF), Frankfurt am Main

72076

University Hospital Tuebingen, Tübingen

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER